TAG:
pathology labs
Sonic Healthcare Buys Clinical Pathology Labs
By Robert Michel | From the Volume XII No. 13 – September 12, 2005 Issue
CEO SUMMARY: It’s one of the most interesting lab acquisitions to take place in the past decade. Pathologist-owners of Austin, Texas-based Clinical Pathology Laboratories, Inc. are selling up to 85% of their lab company to Sonic Healthcare, Ltd, Australia’s largest laboratory firm. Th…
Review of 2004 Lab Sales Identifies Buyer Interest
By Robert Michel | From the Volume XII No. 3 – February 14, 2005 Issue
CEO SUMMARY: Laboratory acquisition activity was surprisingly high during 2004. One reason is that new buyers appeared in the marketplace. However, all buyers have specific acquisition criteria. When a selling lab meets that criteria, it can expect multiple bidders and a strong purchase p…
Analysis of OIG’s Opinion Shows Compliance Shift
By Robert Michel | From the Volume XII No. 1 – January 3, 2005 Issue
CEO SUMMARY: Attorney Richard Cooper believes the latest Advisory Opinion by the Office of the Inspector General (OIG) is consistent with its earlier anti-kickback law pronouncements about situations where a physician is in a position to profit from the patients he/she refers. Cooper also…
Memphis Path Lab JV Purchased By AEL
By Robert Michel | From the Volume XI No. 14 – October 11, 2004 Issue
CEO SUMMARY: Memphis Pathology Labs’ two hospital owners and their JV partner, MDS, surprised many with the sale of the lab venture to American Esoteric Laboratories (AEL). It’s the end of a successful joint venture between several hospitals and a commercial laboratory company. It als…
LabCorp’s Smith Speaks On New Pathology Trend
By Robert Michel | From the Volume XI No. 11 – August 9, 2004 Issue
CEO SUMMARY: During the past decade, Laboratory Corporation of America’s Brad Smith faced the spear point of evolving Medicare/Medicaid compliance initiatives which changed so many laboratory industry business practices. Smith believes that business models for in-house anatomic patholog…
New Esoteric Lab Firm Does Two Acquisitions
By Robert Michel | From the Volume XI No. 6 – April 26, 2004 Issue
CEO SUMMARY: Armed with $70 million, American Esoteric Laboratories (AEL) wants to build a national laboratory that offers a full menu of esoteric tests. It is building a primary laboratory in Dallas, which has one of the nation’s best air transport hubs. ThromboCare Laboratories and Vi…
New Competitors Line Up In Oncology Marketplace
By Robert Michel | From the Volume XI No. 4 – March 15, 2004 Issue
CEO SUMMARY: Local pathology groups are advised to more closely track developments in the national market for oncology testing. Not only is big money targeting cancer testing, but a number of nimble, entrepreneurial start-up companies have begun to compete for specimens. Genzyme’s acqui…
Anatomic Path Trends Portend Deep Changes
By Robert Michel | From the Volume XI No. 1 – January 12, 2004 Issue
CEO SUMMARY: Our biannual review of trends shaping the anatomic pathology profession reveals that a wide range of influences are active. The nation’s healthcare system is undergoing fundamental changes in how it views the quality of health services and how it will favor top-performing p…
Path Trends For 2002 Show Future Direction
By Robert Michel | From the Volume IX No. 1 – January 7, 2002 Issue
CEO SUMMARY: Even as pressures to squeeze costs and consolidate within the pathology profession ease, a different set of market trends is exerting influence. Collectively, these trends portend the end of the small pathology group’s dominance of its local healthcare marketplace. It will …
Analysis of Lab Testing Market Reveals Competitive Shifts
CEO SUMMARY: Even as public lab and anatomic pathology companies enjoy sustained growth in specimen volumes and revenues, fundamental shifts in the basic marketplace have changed the competitive environment. Surprisingly, the most open market segment is anatomic pathology specimens referr…
CURRENT ISSUE

Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.
Topics
- Anatomic Pathology
- Clinical Chemistry
- Clinical Laboratory
- Clinical Laboratory Trends
- Digital Pathology
- Genetic Testing
- In Vitro Diagnostics
- IVD/Lab Informatics
- Lab Intelligence
- Lab Marketplace
- Lab Risk & Compliance
- Laboratory Automation
- Laboratory Billing
- Laboratory Compliance
- Laboratory Equipment
- Laboratory Information Systems
- Laboratory Management
- Lean Six Sigma
- Managed Care Contracts
- Molecular Diagnostics
- Pathology Trends
- People
- Uncategorized